Translational Science in Prostate Cancer

Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Men with Non-Metastatic Castration-Resistant Prostate Cancer – Beyond the Abstract

Written by Stephen J. Freedland, MD

In castration-resistant prostate cancer (CRPC), tumor progression occurs despite low, castrate levels of serum testosterone.1 Non-metastatic CRPC (nmCRPC) is characterized by the absence of detectable metastases and prostate-specific antigen (PSA) levels that continue to rise even though patients continue to receive androgen-deprivation therapy.2 Patients with nmCRPC are at risk of progression to metastatic disease and nmCRPC patients with shorter PSA doubling time (PSADT) have increased risk of metastasis and poorer clinical outcomes.3–5

Treatment of Prostate Cancer With CD46 Targeted 225ac Alpha Particle Radio-Immunotherapy - Beyond the Abstract

Targeted radionuclide therapy is an emerging strategy for treating genitourinary malignancies. PSMA-targeted radiolabeled molecules have shown promising results for both imaging and radiopharmaceutical therapy in prostate cancer. However, a significant fraction of patients are negative for PSMA or develop PSMA negativity during treatment, leading to a lack of response to PSMA-directed radioligand theranostic molecules. Therefore, an unmet need exists to find a biomarker that can be used as an alternative to PSMA in prostate cancer, with several promising targets now under investigation.

Evaluation of Social Determinants of Health and Prostate Cancer Outcomes Among Black and White Patients: A Systematic Review and Meta-analysis - Beyond the Abstract

Immense resources have been dedicated to identifying innate biological differences between Black and White men that could explain the disparities in prostate cancer with the results being equivocal at best. Prostate cancer, the most commonly diagnosed solid organ cancer in men, represents perhaps the greatest disparity in outcomes in oncology.1 Few studies, if any, have attempted to evaluate the association between prostate cancer outcomes and social determinants of health (SDOH).

Price Transparency of Prostate Cancer Care in the United States: An Analysis of Pricing and Disclosure Following the Centers for Medicare and Medicaid Mandate - Beyond the Abstract

The costs incurred for healthcare have historically been opaque, such that patients are often unaware of their treatment costs until their bills come due. To ameliorate this, the Centers for Medicare and Medicaid Services issued a mandate that starting on January 1, 2021, all hospitals in the United States must make the pricing of provided services publicly available on their hospital websites in machine-readable files. We used a dataset that aggregates these publicly-displayed prices to investigate the landscape of pricing for prostate cancer care.

Centers of Excellence

Translational Science in Prostate Cancer

An Introduction to the UroToday “Prostate Cancer Translational Research” Center of Excellence

Centers of Excellence

Translational Science in Prostate Cancer

An Introduction to the UroToday “Prostate Cancer Translational Research” Center of Excellence

Login